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ABSTRACT
Cancer cells need to regulate their metabolic program to fuel several activities, 
including unlimited proliferation, resistance to cell death, invasion and metastasis. 
The aim of this work is to revise this complex scenario. Starting from proliferating 
cancer cells located in well-oxygenated regions, they may express the so-called 
“Warburg effect” or aerobic glycolysis, meaning that although a plenty of oxygen 
is available, cancer cells choose glycolysis, the sole pathway that allows a biomass 
formation and DNA duplication, needed for cell division. Although oxygen does not 
represent the primary font of energy, diffusion rate reduces oxygen tension and the 
emerging hypoxia promotes “anaerobic glycolysis” through the hypoxia inducible 
factor-1α-dependent up-regulation. The acquired hypoxic phenotype is endowed with 
high resistance to cell death and high migration capacities, although these cells are 
less proliferating. Cells using aerobic or anaerobic glycolysis survive only in case they 
extrude acidic metabolites acidifying the extracellular space. Acidosis drives cancer 
cells from glycolysis to OxPhos, and OxPhos transforms the available alternative 
substrates into energy used to fuel migration and distant organ colonization.
Thus, metabolic adaptations sustain different energy-requiring ability of cancer 
cells, but render them responsive to perturbations by anti-metabolic agents, such as 
inhibitors of glycolysis and/or OxPhos.
INTRODUCTION
In genetic unstable tumor cells, environmental 
restrictions may stimulate a rapid emergence of a 
new panel of different subpopulations that may reach 
stable proportions until the next selection pressure(s) is 
encountered. Hence, primary tumors are heterogeneous 
and contain subpopulations of cells that differ in several 
abilities, such as sustained proliferative signaling, 
resistance to cell death, invasion and metastatic 
dissemination [1]. Proliferation, in particular, occurs 
irrespective of external stimuli, as genetic and epigenetic 
alterations favor autocrine growth signaling and 
pathways supporting nutrient uptake and use. Cancer cell 
proliferation relays on availability of necessary substrates 
provided by an adequate blood supply, and, necessarily, 
space as the two major limiting factors. As the cells 
accumulate and periods of possible environmental stress 
may alter rate of proliferation and viability, an additional 
strategy to survive has to adapt. Thereafter, cancer cells 
migrate into surrounding tissues following destruction and 
dissolution of collagen and non-collagenous glycoproteins 
of extracellular matrix, properties related with high 
motility and secretion of proteolytic enzymes. Thus, 
cancer cells have to adjust their energy metabolism to fuel 
different tasks in which are involved [2-4].
Cancer metabolism is now a hot hallmark in cancer, 
which needs to be revised in order to clarify causes and 
consequences [4, 5]. The currently renaissance of cancer 
metabolism also derives from the observation that many 
oncogenic signals driving tumorigenesis are key regulators 
of metabolic network [6, 7]. A classical representation of 
experimental tumors identifies a well oxygenated tumor 
cell subpopulation located in the vicinity to blood vessels 
using lactate to fuel oxidative metabolism and sparing 
glucose, and a distant hypoxic cells using glucose and 
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producing lactate for a metabolic symbiosis model [8] 
Herein, we intend to revise and offer an integrated model 
of metabolic adaptation of cancer cells from proliferation 
to invasion. This view offers the possibility to disclose 
new strategies based on the anti-metabolic supporting 
therapy of tumors.
Metabolic scenario in tumors (see Fig. 1)
Cancer cells undergoing proliferation have to 
stimulate biomass formation and replicate their genome 
before to divide into two daughter cells, for that reason 
the metabolic program of proliferating cancer cells has 
to satisfy the anabolic demands of macromolecular 
biosynthesis. Starting from glucose, the glycolytic flux 
allows generation ATP and biosynthetic precursors of 
several macromolecules, including those generating 
lipids, proteins and nucleic acids, necessary to proliferate. 
This is done via: a) the pentose phosphate pathway and 
involves the nicotinamtide adenine dinucleotide phosphate 
(NADPH) generation, used for ribose-5-phosphate and 
fatty acid synthesis; b) 3-phosphoglycerate (3-PG), 
which may be used for amino acid and lipid synthesis; 
and c) the fraction of pyruvate not converted into lactate 
which furnishes an additional substrate for amino acid 
synthesis (serine, glycine) and, whether transferred into 
the tricarboxylic acid (TCA) cycle, generates citrate 
for lipid biosynthesis and protein acetylation [2, 3, 9]. 
Therefore, mitochondria participate actively in sustaining 
biosynthetic pathways in proliferating cancer cells, and 
an improved uptake of glutamine and glutaminolysis 
reconstitute TCA intermediates to prevent loss of 
mitochondrial integrity [10-11].
Overall, a special, but “not” unexpected, 
characteristic of proliferating cancer cells is a persistence 
in using specially glycolysis, even in presence of a tension 
of oxygen able to support oxidative phosphorylation 
(OxPhos), the so-called “aerobic glycolysis” or “Warburg 
effect” [9, 12, 13]. It is reasonable whether carbon 
molecules were entirely oxidized to CO2 in mitochondria, 
biomass generation from glucose results impossible. 
Elevated glycolysis in cancer cells represents a likely 
constitutive phenomenon, independent from oxygen 
tension. Indeed, c-Myc deregulation is able to promote 
expression of glucose transporters and glycolytic enzymes 
[14-16]. The serine threonine kinase Akt is also known 
as the main inducer of the glucose-lactate pathway, 
inducing glucose transporter, glycolytic enzymes and 
phosphorylation and activation of citrate lyase working 
to increase lipid synthesis [17, 18]. Phosphatidylinositol-
Fig.1: “Inverse pyramid” of metabolic adaptations of tumor cells.
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3-OH kinase (PI3K), Akt and mammalian target of 
rapamycin (mTOR) pathway elicit both expression of 
amino acid transporters and protein translation, thereby 
coordinating protein synthesis; PTEN acts as a regulator of 
this flux of information [3, 4, 9]. Furthermore, cancer cells 
of several tumor histotype express high level and activity 
of pyruvate kinase (PK) M2 type (PKM2) produced by 
alternative splicing of the PKM gene, which catalyzes the 
rate-limiting step of glycolysis, controlling conversion of 
phosphoenolpyruvate (PEP) to pyruvate, and thus ATP 
generation [6, 19]. By slowing the passage of metabolites 
through glycolysis, PKM2 promotes the accumulation of 
large quantities of NADPH and other macromolecules 
needed to support cell division. PKM2 isoform expression 
is controlled by c-Myc [14]. Thus, a well-coordinated 
molecular events may sustain “Warburg effect”.
Glycolysis, although energetically inefficient, 
relative to mitochondrial OxPhos, can satisfy the energetic 
yield and pyruvate for TCA cycle of proliferating cancer 
cells through a more rapid flux and an intense uptake 
of glucose. It is generally accepted that during tumor 
progression an inflammatory response operates locally 
promoting systemic changes, among which a sustained 
decline in insulin sensitivity would allow the redistribution 
of glucose from major consumers (e.g. skeletal muscle) 
to tumor cells. In fact, bioenergetic measurements 
demonstrate that ATP concentrations in tumors is only 
slightly modified in respect to normal tissues, and an 
inefficient ATP generation rises only when substrates 
are limited [20, 21]. The [18F] fluoro-2-deoxyglucose 
(FDG) positron emission tomography (18F-PET) imaging 
of tumors reveals glucose uptake by cancer cells. FDG 
is taken up by glucose transporters and phosphorylated 
by hexokinase enabling tumor tissue visualization [22]. 
Besides, imaging technique indicate that around 30% 
of tumors are not 18F-PET-positive, demonstrating that 
metabolic profile of tumors is not always glycolytic, and 
new metabolic tracers are necessary [23]. 
Although, proliferating cancer cells, which usually 
located near the vascular tree, use more glucose than 
oxygen, oxygenation level can be worsened increasing 
diffusion distance in the tissues. Thus, low oxygen tension 
areas develop promoting a less proliferating, but more 
resistant tumor cell phenotype. A key regulator of cellular 
response to hypoxia is the hypoxia-inducible factor-1 
(HIF-1) transcription factor complex, progressively 
activated in cancer cells by low oxygen tension (mild 
of 7-21 to severe hypoxia of 1.4-0.7 mmHg) [24]. HIF-
1 activity requires the subunit HIF-1α, which works as 
a master-transcriptional activator for a group of genes 
involved in cell survival, angiogenesis, migration, 
energy metabolism and pH regulation [25, 26]. HIF-1α 
increases migration of tumor cells promoting epithelial-
to-mesenchymal transition (EMT) [25], a mesenchymal 
phenotype expressing invasive and motogenic properties, 
crucial in local invasiveness and secondary organ 
colonization [27]. Cells, under HIF-1α control, continue to 
adopt glycolysis (“anaerobic glycolysis”). HIF-1α renders 
cancer cells more efficient in mobilizing the residual 
glucose strengthening glucose transporters (GLUT1 and 
3), and stimulates gene transcription of several proteins 
involved in glucose metabolism, such as aldolase A, 
enolase-1, esokinase 1 and 3, lactate dehydrogenase A 
(LDH-A), phosphofructokinase-1 (PFK-1) and PKM2. 
HIF-1α, concomitantly, represses entry of pyruvate into 
TCA cycle, inhibiting pyruvate dehydrogenase (PDH) 
by pyruvate dehydrogenase kinase (PDK) activation 
[28]. The reduced pyruvate entry into TCA cycle reduces 
intermediates for biosynthesis necessary for proliferating 
cells. It has been found that the reduced citrate synthesis 
can be restored by a significant amount of lipogenic 
acetyl-CoA provided by glutamine, captured at higher rate 
by hypoxic than normoxic cells [29]. Thus, HIF-1α may 
works as a fine-regulator of energy program and migration. 
HIF-1α is also stabilized by PI3K/Akt/mTOR pathway 
activation, indicating a converging activation signaling 
for HIF-1α-dependent glycolysis stabilization [25]. 
Consequence of these changes is a reduced proliferation, 
necessary adaptation to survive in a low substrate-
containing environment. In fact HIF-1α promotes 
block of G1/S transition of cell cycle, affecting cyclin-
dependent p21 and p27 kinases [30]. HIF-1α has also been 
demonstrated to increase resistance of cells to apoptosis 
process [31] and activates Notch and Oct4 signaling that 
control self renewal and multipotency of stem cells [32]. 
A risk of anaerobic glycolysis is the increase lactic acid 
production, that needs to be removed from cells in order 
to avoid a drop in intracellular pH, that could result in 
cell damage. To contrast this effect, HIF-1α induces 
monocarboxylate transporter 4 (MCT4) and carbonic 
anhydrase IX activity that mediate lactic acid efflux 
and catalysis of reversible CO2 hydration, respectively 
[26, 33]. Koukourakis and collegue. [34], report that 
preferential expression of MCT1, which promotes entry 
of lactate into the cell, and LDH-1 together with elevated 
PDH activity in tumor fibroblasts support the metabolic 
use of lactate produced by tumor cells, preventing the 
development of a hostile acidic environment. The Cori 
cycle in the liver may also promote reprocessing lactate 
to glucose, causing a minimum change on energy reserve 
of whole organism. Nevertheless, in tumors there is a pH 
gradient with intracellular greater than extracellular pH, 
reverse of that found in normal tissues. Although acidity is 
“primarily” caused by endogenous metabolism of cancer 
cells choosing “Warburg effect” or anaerobic glycolysis, 
a chaotic vasculature, a reduced intratumoral lymphatic 
vessels and an altered intratumoral fluid dynamics, due to 
increased fluid pressure, participate to extracellular tumor 
acidity development, with a pH value even lower than 6.5 
[35].
The reduced pH of tumor microenvironment now 
triggers in cancer cells, possibly through G-protein-
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coupled receptors (such as OGR1 and GPR4) [36], signals 
to stop dividing and gain new vascularized space in 
adjacent host tissues. Cancer cells with internal pH below 
7.1 do not progress into G1/S phase even when an excess 
of growth factors was applied [37]. Thus, acidic melanoma 
cells undergo epithelial-to-mesenchymal transition (EMT) 
[38], just experienced in hypoxic regions, and reprogram 
their metabolism to a pathway more efficient in ATP 
production starting from residual energetic substrates. A 
reduced extracellular pH favors glycolysis inhibition by 
HIF-1α deregulation [39], and promotes OxPhos pathway 
[40]. Acidosis inhibits glycolytic enzymes including 
phosphofructokinase activity, reduces expression of 
glucose transporters and allows TCA cycle recovering. 
Unlike cells grown at standard pH (pH 7.3), cancer cells 
adapted at pH 6.7 do not exhibit “the Crabtree effect” 
during exposure to high glucose [41]. Low-pH adapted 
cells exposed to high glucose, instead of to progress 
toward glycolysis pathway, express a higher pyruvate 
oxidation [41]. Moreover, it has been demonstrated that 
glucose depletion leading to a declined ATP production 
promotes AMP-activated protein kinase (AMPK), a 
protein kinase complex that regulates cellular energy 
homeostasis, before cells undergo a state of energetic 
failure trigging cell death. AMPK activation promotes 
ATP-generating process such as fatty acid oxidation and 
electron transport, and inhibits ATP-consuming processes, 
such as protein, cholesterol and fatty acid synthesis. 
AMPK-dependent p53 activation negatively regulates 
cell cycle progression, glycolysis flux through inhibition 
PI3K/Akt/mTOR pathway, resulting in a p53-dependent 
metabolic shift toward OxPhos [42, 23]. It has been 
shown that acidosis through a p53-dependent pathway 
disconnects ribose synthesis from oxidative pentose 
phosphate pathway and stimulates glutaminolysis, in order 
to increase bioenergetics capacity and reactive oxygen 
species neutralization [43]. It is fascinating to believe that 
acidosis might play a role in protection of tissues from 
an ischemic damage. Not yet completely understood 
is the role played by NF-kB on tumor cell metabolism, 
although NF-kB is crucial for VEGF-C expression in 
acidic melanoma cells [44]. OxPhos, whether oxygen 
tension is still enough (≥ 3.5 mmHg), may work using 
alternative substrates, such as lactate, free fatty acids and 
amino acids, to satisfy the high energetic demand of high 
motile cancer cells. Thus, lactate produced by glycolytic 
cancer cells, either using Warburg effect or anaerobic 
glycolysis, constitutes an alternative metabolic fuel for 
acidic cancer cells expressing an oxidative metabolism. 
Tumor-associated fibroblasts have been documented to 
participate in lactate homeostasis in tumors. Fibroblasts in 
contact with epithelial cancer cells undergo myofibroblast 
differentiation and produce lactate through aerobic 
glycolysis which is used by cancer cells for respiration 
[45-47]. A chronic exposure to low pH (pH 6.5 medium 
for 8 weeks) stimulates in tumor cells of cervix, colon 
and pharynx tumors a mitochondrial respiration fueled by 
glutamine through Sirt1/HIF2α axis [48].
Migration, on the other hand, is a complex 
process requiring a coordinated action of multiple active 
macromolecules, implicated in adhesiveness, cytoskeletal 
dynamic and digestion of extracellular matrix. It was 
found that melanoma cells reach a maximum of migration 
at pH 7.0 [49] and acidosis promotes in cancer cells an 
aggressive phenotype characterized by high resistance 
to apoptosis, high invasiveness and metastasis, favoring 
lodgment into target organs [38]. Low extracellular 
pH favors activation of several proteases, such as 
metalloproteases (MMP), including MMP-3 and MMP-
9, urokinase-type plasminogen activator, cathepsin B 
and L [35]. MMP-3 and 9 are tightly correlated with the 
induction of EMT in cancer cells, the characteristic profile 
adopted by cancer cells to freely migrate into surrounding 
tissues [38]. Very recently, LeBleu and collegue. indicate 
that circulating cancer cells undergoing EMT characterized 
by a high migratory ability and metastatic dissemination, 
are energetically fuel by mitochondrial biogenesis and 
OxPhos [50]. 
On the whole, front of a tumor may expand 
although at a different rate due to various level of energy 
obtained from OxPhos activity or HIF-1α-dependent 
anaerobic glycolysis. Otherwise, when oxygen is not 
able to sustain OxPhos and environment is anoxic and 
acidic, cells progress irreversibly to death, justifying the 
frequent observation of necrosis in spontaneous tumor 
mass. Whether, cancer cells metastasize distant organs, 
possibly using OxPhos [50], either they may be dormant 
or, in case of adequate blood supply, they may reprogram 
their metabolic profile switching back to an aerobic 
glycolysis pathway, in order to be proliferative; a profile 
probably associated with a mesenchymal-to-epithelial 
transition program. Then, cells again may change to 
anaerobic glycolysis under the HIF-1α-dependence or 
acid-stimulated OxPhos to invade locally and gain new 
space for proliferation.
Metabolic therapy
Whether tumor metabolism might be considered 
“the Achilles’ Heel of tumors” is yet difficult to say, 
however metabolic changes, directly or indirectly, 
accompanied any other property tumor cells acquire 
during progression to malignancy, such as unlimited 
proliferation and invasiveness.
Glycolytic inhibitors are not specific and inhibition 
of glycolysis does not kill tumor cells expressing a 
different metabolic profile. Among glycolytic inhibitors, 
is the non-metabolically competitive inhibitor of glucose, 
the 2-deoxyglucose (2-DG) which is able to suppress 
hexokinase II and cause a depletion of cellular ATP, 
leading to blockage cell cycle progression and cell 
death [51]. However, a dose-dependent toxicity limits 
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its use in human being, although combining 2-DG with 
adryamicin or paclitaxel, it was found to yield an additive 
toxicity in human osteosarcoma and non-small cell lung 
cancers [52]. Other glycolytic inhibitors are: Lonidamine, 
an exokinase inhibitor; some arsenate compounds, 
that abolish ATP generation causing arsenolysis in the 
glyceraldehyde-3-phosphate dehydrogenase reaction; and 
the 3-bromopyruvate (3-BrPA), another potent inhibitor 
of hexokinase II, effective in killing liver cancer cells 
[53]. The ability of 3-BrPA to preferentially kill cancer 
cells with mitochondrial defects and that live in a hypoxic 
environment provides a biochemical basis to further 
develop this class of compounds as novel anticancer 
agents with potentially promising therapeutic activity and 
selectivity [54].
MCTs are overexpressed in many tumors and 
contribute to the maintenance of cellular alkalinity through 
active export (type 4) or import (type 1) of lactate, pyruvate 
and ketone bodies. MCT inhibitors have been shown to 
decrease pHi in neuroblastoma [55] and melanoma cells 
[56], resulting in cell death. By inhibiting MCT1, lactate 
is not available to aerobic cells, so it induces a switch from 
lactate-fuelled respiration to glycolysis, accompanied by 
a retardation of tumor growth in a mouse model of lung 
carcinoma and in transplanted human colorectal carcinoma 
[47]. Several MCT inhibitors have been described but 
none of them is specific, as cyanocinnamate derivatives 
(e.g. α-cyano-4-hydroxycinnamate or CHC), bioflavonoids 
(e.g. phloretin and quercetin), anion transport inhibitors 
(e.g. niflumic acid and 5-nitro-2-(3-phenylpropylamino) 
benzoate or NPPB), or stilbenedilsulfonates (e.g. 
4,4′-dibenzamidostilbene-2,2′-disulfonate or DIDS) 
[57]. A recent MCT1-specific inhibitor, AR-C117977, 
was found to possess immunosuppressive properties 
that prolongs skin graft and heart allograft survival in 
mice [58]. MCT1 knockdown suppressed metastatic 
dissemination of osteosarcoma cells with a mechanism 
related to NF-kB pathway inhibition [59]. 
Metformin (N?,N?-dimethylbiguanide) is one 
of most widely prescribed oral hypoglycemic agent 
used in type 2 diabetes and also in polycystic ovarian 
syndrome (PCOS), where insulin resistance is a key 
factor for metabolic disturbance development. Recently 
Metformin received increased attention, since its use 
may reduce cancer risk [60, 61] and may improve cancer 
prognosis, independently of its hypoglycaemic effect 
[62]. Metformin acts through inhibition of mitochondrial 
respiration by inhibiting complex I of electron transport 
chain and hence is an example of mitochondrial metabolic 
inhibitor blocking oxidative respiration [63], although 
metformin may also acts decreasing levels of insulin and 
insulin-related growth factor. This results in increased 
cellular AMP-to-ATP ratio which, through AMPK 
activation, promotes GLUT1 expression [64] and PFK-2 
phosphorylation stimulating glycolysis [65]. Metformin-
side effect is represented by lactic acidosis, although this 
effect is dose-dependent and dichloroacetate (DCA) may 
be used to treat this metabolic effect. DCA may work 
as anticancer agent working as inhibitor of PDK [66]. 
Metformin is also a potent blocker of cell proliferation 
by inhibiting mTORC1 complex [67, 68] and induces cell 
apoptosis through activating JNK/p38 MAPK pathway 
[69]. In addition, metformin may upregulate several 
mRNAs belonging to energy metabolism pathway and 
downregulates c-Myc, IRS-2 and HIF1α messanger 
RNAs, effective in reducing incidence and mortality in 
breast cancer-bearing mice [70]. Combined treatment 
with metformin and chemotherapeutic agents has been 
studied using in vivo models of breast, prostate and lung 
cancer. One example is the combination of metformin and 
doxorubicin, that kills both mammary cancer stem cells 
and non cancer stem cells [71], or the combination of 
metformin and 2-DG that has a much stronger deleterious 
effect than either drug in prostate cancer [72]. As an 
additional point, it was found that metformin inhibits 
osteosarcoma growth amplifying the effect of cisplatin 
[73]. 
CONCLUSIONS
It is well recognized that tumor microenvironment, 
due to an altered and not completely organized vascular 
network together with a reduced intratumoral lymphatic 
vessels, suffers from ischemic hypoxia which participates 
to acidosis development. Thus, tumor cells need to 
adapt their metabolism to regional variation in glucose 
and oxygen concentration switching from glycolysis to 
OxPhos, in order to proliferate or expand into surrounding 
tissues. Thus, metabolic reprogramming renders cancer 
cells prone to be perturbed by pharmacological agonists 
or antagonists disclosing new opportunities for therapy. 
However, the available metabolic agents are very limited, 
justifying the search for new products targeting metabolic 
pathway of tumor cells.
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